Functional Diagnostics in Washington

Furuno Electric Co., Ltd. is a diversified manufacturer of marine navigation, positioning, and medical equipment. Primary business focuses on marine electronics for recreational boats, merchant marine, fishing vessels, and workboats, including fish finders, sonar systems, multi-beam sonars, marine radar, GPS/GNSS chart plotters, autopilots, and integrated navigation displays. The company also manufactures GPS/GNSS receiver chips and modules for positioning and timing applications, including 5G network infrastructure. In the medical segment, Furuno produces clinical chemistry analyzers and ultrasound bone densitometers for diagnostic and monitoring applications. The company provides navigational equipment training and coastal monitoring systems. Furuno operates with advanced capabilities in GNSS timing technology, autonomous navigation solutions, cyber security, and remote monitoring platforms. The organization serves global maritime markets and has expanded into industrial positioning and healthcare diagnostics. Products meet international maritime standards and regulatory requirements for marine equipment.

Magnolia Medical Technologies develops diagnostic solutions focused on reducing blood culture contamination and improving sepsis diagnostic accuracy. The company's flagship product is the Steripath® Micro Initial Specimen Diversion Device®, an FDA 510(k)-cleared device designed to reduce false-positive blood culture results in sepsis testing. The Steripath Platform is offered in two configurations: Steripath Micro for Direct to Media and Steripath Micro for Syringe Draws, supporting both peripheral venipuncture and peripheral IV start collection methods. Clinical studies demonstrate 83–88% contamination rate reduction depending on collection method. The device addresses a critical clinical challenge: blood culture contamination and misdiagnosis lead to unnecessary broad-spectrum antibiotic use, driving antibiotic resistance, Clostridioides difficile infections, and an estimated $6 billion in annual U.S. healthcare waste. Magnolia's platform is trusted by major hospital systems and health networks including Ascension, Premier, Cardinal Health, VA, Vizient, and HealthTrust, with clinical validation published in peer-reviewed journals including Clinical Infectious Diseases, Journal of Hospital Infection, and American Journal of Medical Quality. The company emphasizes diagnostic stewardship and quality outcomes improvement, with recognition from Newsweek for infection prevention innovation.

BioSynchronicity Corporation is a diagnostic test manufacturer specializing in rapid, point-of-care in vitro immunochromatographic assays for infectious disease detection. The company's primary product is the C-Sync® COVID-19 Antigen Test, an ultra-rapid qualitative assay for SARS-CoV-2 detection authorized under FDA Emergency Use Authorization (EUA220346, issued March 23, 2023). The company also develops the Stayin' Alive™ product line, including multi-drug screening tests. BioSynchronicity operates a team with expertise in technology development, healthcare delivery, and international trade, supported by state-of-the-art R&D capabilities. Manufacturing is conducted under ISO 13485 certified protocols with quality control and assurance supervision. Analytical performance testing is performed by an accredited laboratory in Rockville, Maryland. The company holds CE Mark certification for the European Union with Ministry of Health registration in The Netherlands, and has obtained a Free Sales Certificate for the UAE. BioSynchronicity is positioned to serve markets across the USA, Europe, MENA, and Africa. The company emphasizes affordable, reliable rapid diagnostic testing as a component of integrated infectious disease mitigation strategies.

Immunexpress develops rapid diagnostic technology for sepsis detection based on immune response biomarker analysis. The company's flagship product, SeptiCyte® RAPID, is a fully automated cartridge compatible with the Biocartis Idylla™ platform that quantifies and analyzes gene expression from whole blood samples to diagnose sepsis in suspected patients within one hour—compared to traditional testing methods that require 24–48 hours and produce actionable results in only 20% of cases. SeptiCyte® RAPID delivers clinically actionable results for 100% of tested patients. The technology addresses a critical clinical need: sepsis remains the leading cause of death in hospitals globally (11 million deaths annually among 49 million cases), yet early detection is hampered by inadequate diagnostic tools. By enabling rapid diagnosis, Immunexpress's solution aims to reduce mortality rates, shorten hospital stays, and lower healthcare costs. The company targets acute care hospitals and clinicians managing suspected sepsis cases across intensive care and emergency departments. Manufacturing and delivery are achieved through partnership with Biocartis, leveraging their Idylla™ automated molecular analysis platform.

InBios International, Inc. is a privately-held biotechnology company specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and biothreats. Founded in 1996 and headquartered in Seattle, Washington, the company operates a state-of-the-art GMP-compliant, FDA-registered manufacturing facility certified to ISO 13485:2016. InBios maintains a portfolio of over 25 FDA-cleared diagnostic products and extensive life science reagent catalogs. Core offerings include ELISA kits, rapid point-of-care tests, and contract manufacturing services for emerging infectious disease diagnostics. The company delivers immunoassays targeting dengue, West Nile virus, Zika, Chagas disease, leishmaniasis, COVID-19, influenza, and biothreats such as anthrax and melioidosis. InBios provides comprehensive assay development, regulatory affairs support, and contract manufacturing capabilities to clinical laboratories, public health agencies, research institutions, and OEM partners globally. The company is recognized for rapid response to emerging disease threats while maintaining rigorous quality standards and cost-effective solutions for the global diagnostic market.

D. E. Hokanson, Inc. designs, manufactures and sells noninvasive diagnostic instruments for vascular assessment and peripheral vascular disease diagnosis. Founded in 1973, the company specializes in blood flow measurement and vascular testing equipment, including vascular Dopplers, plethysmographs, cuff inflators, and vascular cuffs. Products serve vascular specialists, primary care physicians, cardiologists, endocrinologists, wound care professionals, and clinical researchers. The company manufactures all products in the USA and offers a comprehensive 5-year warranty. Hokanson instruments utilize pulse wave Doppler, continuous wave Doppler, and plethysmography technologies to facilitate noninvasive peripheral vascular physiological testing, ankle-brachial index (ABI) measurement, toe pressure assessment, and venous reflux evaluation. Applications include peripheral artery disease (PAD) screening, diabetes-related vascular complications, wound care assessment, and vascular research.